Search results
Results from the WOW.Com Content Network
Treatment for CMV infection should start at 1 month of age and should occur for 6 months. The options for treatment are intravenous ganciclovir and oral valganciclovir. After diagnosis, it is important to further investigate any possible evidence of end-organ disease and symptoms through blood tests, imaging, ophthalmology tests, and hearing tests.
The CMV pp65 assay is widely used for monitoring CMV infection and its response to antiviral treatment in people who are under immunosuppressive therapy and have had renal transplantation surgery, as the antigenemia results are obtained about 5 days before the onset of symptomatic CMV disease.
Diseases associated with HHV-5 include mononucleosis and pneumonia, [4] [5] and congenital CMV in infants can lead to deafness and ambulatory problems. [6] In the medical literature, most mentions of CMV without further specification refer implicitly to human CMV. Human CMV is the most studied of all cytomegaloviruses. [7]
Most commonly, valganciclovir or ganciclovir are used as first-line antiviral therapy for congenital CMV. [11] If the cause is a malignancy, the patient should receive cancer treatment such as chemotherapy. [6] Overall, treatment of the blueberry muffin baby is centered around the underlying cause.
Early in infancy, hepatosplenomegaly, jaundice, hemolytic anemia, thrombocytopenia purpura, pneumonitis, chorioretinitis, and central nervous system (CNS) disease are among the numerous clinical presentations of congenital cytomegalic inclusion disease (CID). Several studies have highlighted the mental and motor retardation caused by chronic ...
The treatment was growing in popularity through the 1990s until a 2002 study suggested it elevated all kinds of health risks, including breast cancer. This jump-started a two-decade-long aversion ...
Cytomegalovirus (CMV) is the most common congenital viral infection, usually transmitted through the placenta during pregnancy. Most neonates with congenital CMV infection will not have any symptoms, but a minority of infected newborns will have symptomatic infection.
A phase 2 study of a recombinant gB protein subunit CMV-vaccine published in 2009 indicated an efficacy of 50% in seronegative women of childbearing age—thus the protection provided was limited and a number of subjects contracted CMV infection despite the vaccination. In one case congenital CMV was encountered. [2] [10]